CLINICAL_TRIALS
trial_result
· 2019-12-16
Clinical Trial Update: Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) [Phase 2]
Summary
Phase 2 long-term extension trial of KRN23 (burosumab) in adults with X-Linked Hypophosphatemia has completed; results were posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kyowa Kirin, Inc. | Conditions: X-Linked Hypophosphatemia | Phase 2 | Status: COMPLETED | Results posted: 2019-12-16